Update on Alzheimer's Disease Therapy and Prevention Strategies.
暂无分享,去创建一个
[1] B. Ebert,et al. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.
[2] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[3] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[4] R. Tanzi,et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease , 2016, Science Translational Medicine.
[5] L. Schneider,et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society , 2016, The Lancet Neurology.
[6] Michele Vendruscolo,et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation , 2016, Nature Communications.
[7] T. Möller,et al. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease , 2016, Glia.
[8] E. Mandelkow,et al. Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.
[9] M. Colonna,et al. Regulation of microglial survival and proliferation in health and diseases. , 2015, Seminars in immunology.
[10] B. Winblad,et al. Proton myo‐inositol cotransporter is a novel γ‐secretase associated protein that regulates Aβ production without affecting Notch cleavage , 2015, The FEBS journal.
[11] Regulation of human MAPT gene expression , 2015, Molecular Neurodegeneration.
[12] E. Sigurdsson,et al. Tau immunotherapy for Alzheimer's disease. , 2015, Trends in molecular medicine.
[13] E. Mandelkow,et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau , 2015, Acta neuropathologica communications.
[14] V. Perry,et al. Microglial Dynamics and Role in the Healthy and Diseased Brain , 2015, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[15] A. Lucia,et al. Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect , 2015, Drugs & Aging.
[16] Thomas Tuschl,et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. , 2015, The Journal of clinical investigation.
[17] J. Trojanowski,et al. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice , 2015, Neurobiology of Disease.
[18] Thomas C. Baddeley,et al. Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[19] J. Morrison,et al. Glutamatergic regulation prevents hippocampal-dependent age-related cognitive decline through dendritic spine clustering , 2014, Proceedings of the National Academy of Sciences.
[20] N. Zilka,et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model , 2014, Alzheimer's Research & Therapy.
[21] C. Dobson,et al. The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.
[22] L. Grinberg,et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.
[23] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[24] E. Hol,et al. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice , 2014, Neurobiology of Aging.
[25] M. Goedert,et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice , 2013, Acta Neuropathologica.
[26] Shengxiang Zhang,et al. Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke. , 2013, Brain : a journal of neurology.
[27] F. van Leuven,et al. Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.
[28] K. Scearce-Levie,et al. A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .
[29] D. Holtzman,et al. Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.
[30] E. Siemers,et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.
[31] The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques , 2013, Acta Neuropathologica.
[32] Alexander K. Buell,et al. Influence of specific HSP70 domains on fibril formation of the yeast prion protein Ure2 , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.
[33] V. Perry,et al. Regulation of Microglial Proliferation during Chronic Neurodegeneration , 2013, The Journal of Neuroscience.
[34] K. Schindowski,et al. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? , 2013, Immunity & Ageing.
[35] E. Mandelkow,et al. The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush , 2012, Proceedings of the National Academy of Sciences.
[36] V. Laporte,et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.
[37] K. Blennow,et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[38] M. V. Nogués,et al. Exploring New Biological Functions of Amyloids: Bacteria Cell Agglutination Mediated by Host Protein Aggregation , 2012, PLoS pathogens.
[39] D. Raleigh,et al. Nucleobindin 1 caps human islet amyloid polypeptide protofibrils to prevent amyloid fibril formation. , 2012, Journal of molecular biology.
[40] Michele Vendruscolo,et al. From macroscopic measurements to microscopic mechanisms of protein aggregation. , 2012, Journal of molecular biology.
[41] B. Winblad,et al. Erlin-2 is associated with active γ-secretase in brain and affects amyloid β-peptide production. , 2012, Biochemical and biophysical research communications.
[42] B. Winblad,et al. Identification of two novel synaptic γ-secretase associated proteins that affect amyloid β-peptide levels without altering Notch processing , 2012, Neurochemistry International.
[43] A. Ittner,et al. Lessons from Tau-Deficient Mice , 2012, International journal of Alzheimer's disease.
[44] M. Leissring,et al. Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[45] F. Lee,et al. Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027 , 2012, The Journal of Neuroscience.
[46] R. Nussinov,et al. Antimicrobial properties of amyloid peptides. , 2012, Molecular pharmaceutics.
[47] J. Trojanowski,et al. The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice , 2012, The Journal of Neuroscience.
[48] H. Loetscher,et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.
[49] J. Hardy,et al. Twenty years of Alzheimer’s disease‐causing mutations , 2012, Journal of neurochemistry.
[50] K. Scearce-Levie,et al. A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.
[51] Arun K. Ghosh,et al. β-Secretase as a therapeutic target for Alzheimer’s disease , 2008, Neurotherapeutics.
[52] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[53] R. Ransohoff. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. , 2009, Immunity.
[54] L. Wilkins. Association between late-life body mass index and dementia: The Kame Project , 2009, Neurology.
[55] Yaakov Stern,et al. Physical activity, diet, and risk of Alzheimer disease. , 2009, JAMA.
[56] Raphael Kopan,et al. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.
[57] J. McCarthy,et al. Presenilin-dependent regulated intramembrane proteolysis and γ-secretase activity , 2009, Cellular and Molecular Life Sciences.
[58] L. Gan,et al. Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease , 2008, Neuron.
[59] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[60] T. Comery,et al. Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade , 2008, Proceedings of the National Academy of Sciences.
[61] M. Wolfe. γ-Secretase Modulators , 2007 .
[62] H. Kettenmann,et al. Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.
[63] Dag Sehlin,et al. Sensitive ELISA detection of amyloid‐β protofibrils in biological samples , 2007 .
[64] S. Gauthier,et al. Alzhemed: a potential treatment for Alzheimer's disease. , 2007, Current Alzheimer research.
[65] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[66] K. Yaffe,et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.
[67] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[68] Huaxi Xu,et al. Calnuc binds to Alzheimer’s β‐amyloid precursor protein and affects its biogenesis , 2006, Journal of neurochemistry.
[69] L. Lannfelt,et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. , 2007, Journal of neurochemistry.
[70] M. Wolfe. gamma-Secretase modulators. , 2007, Current Alzheimer research.
[71] L. Mucke,et al. Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease , 2006, Neuron.
[72] Stuart Maudsley,et al. Caloric restriction and intermittent fasting: Two potential diets for successful brain aging , 2006, Ageing Research Reviews.
[73] A D Roses,et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.
[74] S. Craft,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.
[75] M. Folstein,et al. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.
[76] H. Steinhoff,et al. Global hairpin folding of tau in solution. , 2006, Biochemistry.
[77] M. Leissring. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. , 2006, Current Alzheimer research.
[78] Hilkka Soininen,et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.
[79] Thomas Klockgether,et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice , 2005 .
[80] L. Lue,et al. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. , 2005, Current drug targets. CNS and neurological disorders.
[81] M. Arbel,et al. Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[82] M. Higuchi,et al. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation , 2005, Nature Medicine.
[83] Nobuhisa Iwata,et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. , 2005, Nature medicine.
[84] Michael T Heneka,et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. , 2005, Brain : a journal of neurology.
[85] Jay S. Fine,et al. Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.
[86] D. Holtzman,et al. Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy , 2004 .
[87] D. Sparks,et al. Dystrophic microglia in the aging human brain , 2004, Glia.
[88] G. Higgins,et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. , 2004, The Journal of biological chemistry.
[89] D. Holtzman,et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. , 2004, Journal of molecular biology.
[90] W. H. Jordan,et al. Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor* , 2003, Journal of Biological Chemistry.
[91] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[92] P. Muchowski. Protein Misfolding, Amyloid Formation, and Neurodegeneration A Critical Role for Molecular Chaperones? , 2002, Neuron.
[93] L. Launer,et al. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.
[94] F. Hartl,et al. Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.
[95] D. Selkoe. Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.
[96] B. Solomon,et al. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[97] C. Franceschi,et al. Inflamm‐aging: An Evolutionary Perspective on Immunosenescence , 2000 .
[98] E. Mandelkow,et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[99] J. Hardy,et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.
[100] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[101] B. Winblad,et al. Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.
[102] K. Jellinger,et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.
[103] B. Solomon,et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .
[104] B. Solomon,et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[105] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[106] B. Solomon,et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[107] A. Schmidt,et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.
[108] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[109] K. Titani,et al. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. , 1992, Biochemical and biophysical research communications.
[110] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[111] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[112] J. Walker,et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.